Sep 2026· Zhonghua yi xue za zhi· Vol 106 32, pp.
3360-3367
· 0 citations
Medicine
TL;DR
In patients with advanced gastric cancer after first-line chemotherapy for disease control, there is no statistically significant difference in the efficacy of maintenance therapy with or without Pembrolizumab combined with chemotherapy, and it can reduce the cumulative toxicity caused by continuous chemotherapy.
Objective. To evaluate the efficacy and safety of atezolizumab in combination with carboplatin and etoposide in the first-line treatment of advanced small cell lung cancer (SCLC) in real-life clinical practice. Material and methods. A retrospective single-center cohort study was conducted. The analysis included 58 cons...
D. М. Ponomarenko, K. Titov, D. Yukal'chuk et al.· P.A. Herzen Journal of Oncol...· 0 citations
Reduced-dose chemotherapy plus nivolumab may be an effective and less toxic first-line option for elderly patients with AGC, according to retrospectively collected clinical data from 70 patients aged 70 years or older with AGC.
Toshihiko Matsumoto, S. Sugimoto, R. Omori et al.· Gastroenterology Insights· 0 citations
Maintenance capecitabine after first-line modified FOLFIRINOX in patients with metastatic pancreatic cancer was well tolerated and may enhance PFS and OS while maintaining an acceptable quality of life.
M. Shehata, A. Alhanafy, Mohamed Hassan et al.· Asian Pacific Journal of Can...· 0 citations
Background/Objectives: We evaluated the efficacy and safety of first-line treatment with a programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy versus chemotherapy alone in patients aged ≥75 years with extensive-stage small cell lung cancer (ES-SCLC). Methods: We retrospectively analyzed the pat...
OBJECTIVES
The optimal first-line treatment for advanced large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. This study aimed to comprehensively evaluate and compare the efficacy of different first-line treatment regimens in patients with stage IIIB/IV LCNEC.
METHODS
A retrospective analysis was...
Zhuo-Ran Li, Zhi-Xiu Xu, Luo-Nan Wang et al.· American journal of translat...· 0 citations
Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.
Nguyen H. Tran, M. Palmer, Angela Ulrich et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
